Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Equillium, Inc. (EQ)
USD2.57
-0.19 (-6.82%)
US NASDAQ S&P 500
Healthcare Biotechnology
Address
2223 Avenida De La Playa 92037
La Jolla, CA, US
La Jolla, CA, US
CEO
Bruce D. Steel
Website
equilliumbio.com
IPO
2018-10-12
CIK 1746466 ISIN US29446K1060
Description
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Metacrine, Inc. | MTCR | 2022-10-26 | View |
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2006-05-17 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.57
-0.19 (-6.82%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
731.1K
Beta
1.77
Float Shares
17.54M
Free Float %
49.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.76% | +7.44% | +35.88% | +47.13% | +175.00% | +49.03% | +504.55% | +239.71% | -56.00% | -83.50% | -83.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
2.57
Low
6.00
+133.3%
Consensus
6.50
+152.7%
Median
6.50
+152.7%
High
7.00
+172.2%
DCF (Unlevered)
0.32
-87.7%
DCF (Levered)
0.32
-87.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
7.00
+172.2%
|
| Last Quarter | 2 |
6.50
+152.7%
|
| Last Year | 2 |
6.50
+152.7%
|
| All Time | 3 |
4.67
+81.6%
|
Quality scores
Altman Z-Score
8.85
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-99.7%
-
EPS growth Biotechnology: +29.7%-69.6% Q1'26: +75.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-19,910.0%
-
EBIT margin Biotechnology: +0.0%-18,180.0%
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+159.9% Q1'26: +170.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 6 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
15.76M
est: 18.00M (-12.5%)
|
36.08M
est: 42.62M (-15.3%)
|
41.10M
est: 36.85M (+11.5%)
|
130.0K
est: 11.00M (-98.8%)
|
15.58M
15.58M – 15.58M
+41.6% YoY
|
16.52M
16.52M – 16.52M
+6.1% YoY
|
51.69M
51.69M – 51.69M
+212.8% YoY
|
89.24M
89.24M – 89.24M
+72.6% YoY
|
154.8K
154.8K – 154.8K
-99.8% YoY
|
| EBITDA |
-61.26M
est: 1.73M (-3,649.1%)
|
-12.14M
est: -12.96M (+6.4%)
|
-7.57M
est: -11.21M (+32.5%)
|
-23.52M
est: -3.35M (-603.0%)
|
-4.74M
-4.74M – -4.74M
-41.6% YoY
|
-5.03M
-5.03M – -5.03M
-6.1% YoY
|
-15.72M
-15.72M – -15.72M
-212.8% YoY
|
-27.14M
-27.14M – -27.14M
-72.6% YoY
|
-47.1K
-47.1K – -47.1K
+99.8% YoY
|
| EBIT |
-61.38M
est: 1.70M (-3,707.3%)
|
-12.26M
est: -13.02M (+5.8%)
|
-7.71M
est: -11.26M (+31.5%)
|
-23.63M
est: -3.36M (-603.3%)
|
-4.76M
-4.76M – -4.76M
-41.6% YoY
|
-5.05M
-5.05M – -5.05M
-6.1% YoY
|
-15.79M
-15.79M – -15.79M
-212.8% YoY
|
-27.26M
-27.26M – -27.26M
-72.6% YoY
|
-47.3K
-47.3K – -47.3K
+99.8% YoY
|
| Net Income |
-62.43M
est: -59.05M (-5.7%)
|
-13.34M
est: -21.74M (+38.7%)
|
-8.07M
est: -20.19M (+60.1%)
|
-22.40M
est: -37.90M (+40.9%)
|
-25.31M
-26.83M – -16.65M
+33.2% YoY
|
-22.82M
-29.41M – -16.23M
+9.8% YoY
|
-31.47M
-42.27M – -20.66M
-37.9% YoY
|
-31.06M
-31.06M – -31.06M
+1.3% YoY
|
-37.90M
-37.90M – -37.90M
-22.0% YoY
|
| SGA |
17.24M
est: 13.54M (+27.3%)
|
13.57M
est: 731.14M (-98.1%)
|
11.94M
est: 632.14M (-98.1%)
|
10.79M
est: 188.69M (-94.3%)
|
267.18M
267.18M – 267.18M
+41.6% YoY
|
283.45M
283.45M – 283.45M
+6.1% YoY
|
886.70M
886.70M – 886.70M
+212.8% YoY
|
1.53B
1.53B – 1.53B
+72.6% YoY
|
2.66M
2.66M – 2.66M
-99.8% YoY
|
| EPS |
-3.19
est: -1.67 (-91.0%)
|
-0.38
est: -0.24 (-60.6%)
|
-0.23
est: -0.38 (+38.7%)
|
-0.39
est: -0.41 (+5.5%)
|
-0.21
-0.29 – -0.18
+48.7% YoY
|
-0.24
-0.32 – -0.18
-14.9% YoY
|
-0.30
-0.46 – -0.22
-21.5% YoY
|
-0.34
-0.34 – -0.34
-14.6% YoY
|
-0.41
-0.41 – -0.41
-22.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-17 | Roth Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-20.94M
OE per share TTM
-0.45
Owner's Yield
-9.42%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
13
Total invested
11.42M
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Xiangmin Cui | 5.73M | 19.70% | — | — | — | — | PN | — | 2021-02-16 | ↗ |
| 2 | Decheng Capital Management III (Cayman), LLC | 4.45M | 15.13% | 4.45M | 4.45M | 4.45M | 4.45M | IA | OR PLACE OF ORGANIZATION | 2022-02-14 | ↗ |
| 3 | IV, L.P. | 4.27M | 14.70% | — | — | — | — | PN | — | 2021-02-16 | ↗ |
| 4 | LLC | 4.27M | 14.70% | — | — | — | — | OO | — | 2021-02-16 | ↗ |
| 5 | Victory Capital Management Inc. | 4.13M | 14.04% | 4.13M | — | 4.13M | — | IA | New York | 2022-02-01 | ↗ |
| 6 | Takeda Pharmaceutical Company Limited | 1.84M | 5.20% | — | 1.84M | — | — | CO | — | 2024-01-19 | ↗ |
| 7 | Takeda Ventures, Inc. | 1.84M | 5.20% | — | 1.84M | — | — | CO | — | 2024-01-19 | ↗ |
| 8 | (Master), LP | 1.46M | 5.00% | — | — | — | — | PN | — | 2021-02-16 | ↗ |
| 9 | Decheng Capital Global Healthcare GP, LLC | 1.46M | 5.00% | — | — | — | — | OO | — | 2021-02-16 | ↗ |
| 10 | Partner Fund Management, L.P. | 6.00 | 7.20% | — | 1.21M | — | 1.21M | IA, PN, IN | Delaware | 2018-10-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
13
-28 vs prev Q
New positions
6
Closed positions
30
Increased
10
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 5.86M +5.9M (+100.0%) | 9.06M +9.1M (+100.0%) | 16.41% +16.412 pp | 0.00% +0.004 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 2 | ADAR1 CAPITAL MANAGEMENT, LLC | 5.61M +48.1K (+0.9%) | 8.69M +741.7K (+9.3%) | 15.70% +0.135 pp | 0.64% -0.108 pp | USD1.43 +8.4% | 2 qtrs — |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.33M +— (+0.0%) | 8.26M +639.5K (+8.4%) | 14.92% +0.000 pp | 0.01% +0.000 pp | USD1.43 +8.4% | 2 qtrs — |
| 4 | DECHENG CAPITAL LLC | 4.45M +— (+0.0%) | 6.89M +533.7K (+8.4%) | 12.45% +0.000 pp | 0.93% -0.182 pp | USD0.72 +115.3% | 9 qtrs — |
| 5 | WOODLINE PARTNERS LP | 3.50M -7.9K (-0.2%) | 5.43M +408.9K (+8.1%) | 9.80% -0.022 pp | 0.02% -0.003 pp | USD1.43 +8.4% | 2 qtrs — |
| 6 | ABRDN PLC | 2.37M +2.0M (+523.6%) | 3.67M +3.1M (+575.9%) | 6.63% +5.563 pp | 0.01% +0.005 pp | USD1.53 +1.3% | 2 qtrs — |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 2.08M +72.6K (+3.6%) | 3.22M +353.0K (+12.3%) | 5.81% +0.203 pp | 0.00% +0.001 pp | USD1.43 +8.4% | 2 qtrs — |
| 8 | VANGUARD GROUP INC | 1.92M +606.5K (+46.2%) | 2.98M +1.1M (+58.4%) | 5.38% +1.698 pp | 0.00% +0.000 pp | USD3.54 -56.2% | 29 qtrs — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 733.2K +118.3K (+19.2%) | 1.14M +257.2K (+29.2%) | 2.05% +0.331 pp | 0.00% +0.001 pp | USD1.19 +30.3% | 15 qtrs — |
| 10 | CANTOR FITZGERALD, L. P. | 562.6K +137.6K (+32.4%) | 872.1K +264.3K (+43.5%) | 1.58% +0.385 pp | 0.01% +0.007 pp | USD1.46 +6.2% | 2 qtrs — |
| 11 | HUDSON BAY CAPITAL MANAGEMENT LP | 428.5K +150.0K (+53.9%) | 664.2K +265.9K (+66.8%) | 1.20% +0.420 pp | 0.00% +0.001 pp | USD1.47 +5.4% | 2 qtrs — |
| 12 | DIADEMA PARTNERS LP | 347.4K +47.4K (+15.8%) | 538.5K +109.5K (+25.5%) | 0.97% +0.133 pp | 0.09% -0.017 pp | USD1.45 +6.9% | 2 qtrs — |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 345.3K +34.5K (+11.1%) | 535.3K +90.8K (+20.4%) | 0.97% +0.097 pp | 0.00% +0.000 pp | USD3.42 -54.7% | 22 qtrs — |
| 14 | TWO SIGMA INVESTMENTS, LP | 324.6K +191.6K (+144.1%) | 503.1K +313.0K (+164.5%) | 0.91% +0.536 pp | 0.00% +0.000 pp | USD1.50 +3.3% | 2 qtrs — |
| 15 | IKARIAN CAPITAL, LLC | 303.6K -28.7K (-8.6%) | 470.5K -4.7K (-1.0%) | 0.85% -0.081 pp | 0.04% -0.011 pp | USD1.43 +8.4% | 2 qtrs — |
| 16 | TUDOR INVESTMENT CORP ET AL | 258.8K +258.8K (+100.0%) | 401.1K +401.1K (+100.0%) | 0.72% +0.725 pp | 0.00% +0.001 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 185.7K +185.7K (+100.0%) | 287.8K +287.8K (+100.0%) | 0.52% +0.520 pp | 0.00% +0.000 pp | USD1.55 +0.0% | 8 qtrs — |
| 18 | STATE STREET CORP | 155.4K +17.9K (+13.0%) | 240.9K +44.2K (+22.5%) | 0.44% +0.050 pp | 0.00% +0.000 pp | USD2.92 -46.9% | 19 qtrs — |
| 19 | BLACKROCK, INC. | 126.1K +— (+0.0%) | 195.4K +15.1K (+8.4%) | 0.35% +0.000 pp | 0.00% +0.000 pp | USD1.43 +8.4% | 6 qtrs — |
| 20 | JANE STREET GROUP, LLC | 100.9K +100.9K (+100.0%) | 156.3K +156.3K (+100.0%) | 0.28% +0.282 pp | 0.00% +0.000 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 21 | BOOTHBAY FUND MANAGEMENT, LLC | 93.2K -28.7K (-23.6%) | 144.5K -29.9K (-17.2%) | 0.26% -0.081 pp | 0.00% 0.000 pp | USD1.43 +8.4% | 2 qtrs — |
| 22 | PERSISTENT ASSET PARTNERS LTD | 93.1K +24.1K (+35.0%) | 144.3K +45.7K (+46.3%) | 0.26% +0.068 pp | 0.06% -0.003 pp | USD1.46 +6.2% | 2 qtrs — |
| 23 | NORTHERN TRUST CORP | 88.5K +53.5K (+152.8%) | 137.2K +87.1K (+174.0%) | 0.25% +0.150 pp | 0.00% +0.000 pp | USD3.21 -51.7% | 22 qtrs — |
| 24 | ROYAL BANK OF CANADA | 79.7K +79.7K (+100.0%) | 124.0K +124.0K (+100.0%) | 0.22% +0.223 pp | 0.00% +0.000 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 25 | CITADEL ADVISORS LLC | 79.6K +79.6K (+100.0%) | 123.4K +123.4K (+100.0%) | 0.22% +0.223 pp | 0.00% +0.000 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 26 | ALPHACORE CAPITAL LLC | 52.3K +— (+0.0%) | 81.1K +6.3K (+8.4%) | 0.15% +0.000 pp | 0.00% -0.001 pp | USD0.32 +384.4% | 3 qtrs — |
| 27 | TWO SIGMA ADVISERS, LP | 44.1K +44.1K (+100.0%) | 68.4K +68.4K (+100.0%) | 0.12% +0.124 pp | 0.00% +0.000 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 28 | MORGAN STANLEY | 35.7K +25.6K (+254.3%) | 55.4K +41.0K (+284.1%) | 0.10% +0.072 pp | 0.00% +0.000 pp | USD1.35 +14.8% | 5 qtrs — |
| 29 | SCHONFELD STRATEGIC ADVISORS LLC | 25.4K -99.4K (-79.7%) | 39.3K -139.2K (-78.0%) | 0.07% -0.278 pp | 0.00% -0.001 pp | USD1.43 +8.4% | 2 qtrs — |
| 30 | APOLLON WEALTH MANAGEMENT, LLC | 13.9K +— (+0.0%) | 21.5K +1.7K (+8.4%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD0.32 +384.4% | 3 qtrs — |
| 31 | COASTAL BRIDGE ADVISORS, LLC | 10.5K +10.5K (+100.0%) | 16.3K +16.3K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.001 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 32 | TOWER RESEARCH CAPITAL LLC (TRC) | 4.1K -2.3K (-36.5%) | 6.3K -2.9K (-31.1%) | 0.01% -0.007 pp | 0.00% 0.000 pp | USD0.70 +121.4% | 5 qtrs — |
| 33 | WELLS FARGO & COMPANY/MN | 1.0K +— (+0.0%) | 1.6K +120.0 (+8.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.82 -77.3% | 20 qtrs — |
| 34 | UBS GROUP AG | 920.00 -27.1K (-96.7%) | 1.4K -38.7K (-96.4%) | 0.00% -0.076 pp | 0.00% +0.000 pp | USD0.32 +384.4% | 7 qtrs — |
| 35 | BANK OF AMERICA CORP /DE/ | 295.00 +21.0 (+7.7%) | 457.00 +65.0 (+16.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.98 +58.2% | 9 qtrs — |
| 36 | SBI SECURITIES CO., LTD. | 283.00 -162.0 (-36.4%) | 439.00 -197.0 (-31.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD0.70 +121.4% | 5 qtrs — |
| 37 | JONES FINANCIAL COMPANIES LLLP | 250.00 +250.0 (+100.0%) | 388.00 +388.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.55 +0.0% | 1 qtrs NEW |
| 38 | MARSHALL WACE, LLP | — -41.2K (-100.0%) | — -58.9K (-100.0%) | 0.00% -0.115 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 39 | STEMPOINT CAPITAL LP | — -1.9M (-100.0%) | — -2.7M (-100.0%) | 0.00% -5.344 pp | 0.00% -0.547 pp | USD— | 2 qtrs SOLD |
| 40 | RISE ADVISORS, LLC | — -263.0 (-100.0%) | — -376.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 41 | FMR LLC | — -200.0 (-100.0%) | — -286.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 42 | ENGINEERS GATE MANAGER LP | — -39.7K (-100.0%) | — -56.8K (-100.0%) | 0.00% -0.111 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 43 | TWO SIGMA SECURITIES, LLC | — -10.5K (-100.0%) | — -15.1K (-100.0%) | 0.00% -0.030 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 44 | MILLENNIUM MANAGEMENT LLC | — -24.4K (-100.0%) | — -34.8K (-100.0%) | 0.00% -0.068 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 45 | BARCLAYS PLC | — -104.0 (-100.0%) | — -87.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 46 | VIRTU FINANCIAL LLC | — -23.8K (-100.0%) | — -34.0K (-100.0%) | 0.00% -0.067 pp | 0.00% -0.002 pp | USD— | 6 qtrs SOLD |
| 47 | SIMPLEX TRADING, LLC | — -1.9K (-100.0%) | — -2.0K (-100.0%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
| 48 | PRUDENTIAL FINANCIAL INC | — -28.3K (-100.0%) | — -40.5K (-100.0%) | 0.00% -0.079 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 16 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.50% | 110.1K | 0.20% |
| 2 | iShares Micro-Cap ETF IWC | 0.03% | 429.8K | 0.60% |
| 3 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 77.6K | 0.25% |
| 4 | Vanguard Extended Market ETF VXF | 0.00% | 976.5K | 0.05% |
| 5 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 23.2K | 0.43% |
| 6 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 1.7K | 0.17% |
| 7 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 8.6K | 0.03% |
| 8 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 23.7K | 0.17% |
| 9 | Vanguard Total Stock Market ETF VTI | 0.00% | 4.04M | 0.03% |
| 10 | Dimensional - US Small Cap ETF DFAS | 0.00% | 22.7K | 0.26% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.22
Neutral
Ratio by volume
3.00
Bullish
Buys
11
Sells
9
Shares acquired
4.37M
Shares disposed
820.6K
Cash buys
—
Cash sales
6.00
Net activity
+3,553,672
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | Zedelmayer Christine | Officer | M-Exempt | A | Common Stock | 120,312 | 0.79 | 94.4K | 182,898 | D | ↗ |
| 2026-03-09 | Zedelmayer Christine | Officer | M-Exempt | A | Common Stock | 75,000 | 0.79 | 58.9K | 243,805 | D | ↗ |
| 2026-02-19 | Zedelmayer Christine | Officer | M-Exempt | A | Common Stock | 109,375 | 0.79 | 85.9K | 300,819 | D | ↗ |
| 2026-01-08 | Tom Penny | Officer | S-Sale | D | Common Stock | 6,533 | 1.29 | 8.4K | 0 | D | ↗ |
| 2026-01-07 | Zedelmayer Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 500,000 | 1.31 | 655.0K | 500,000 | D | ↗ |
| 2026-01-07 | Tom Penny | Officer | A-Award | A | Employee Stock Option (right to buy) | 450,000 | 1.31 | 589.5K | 450,000 | D | ↗ |
| 2026-01-07 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 1,750,000 | 1.31 | 2.29M | 1,750,000 | D | ↗ |
| 2026-01-07 | Connelly Stephen | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,150,000 | 1.31 | 1.51M | 1,150,000 | D | ↗ |
| 2025-12-23 | Zedelmayer Christine | Officer | M-Exempt | A | Common Stock | 100,000 | 0.79 | 78.5K | 191,444 | D | ↗ |
| 2025-12-15 | Zedelmayer Christine | Officer | S-Sale | D | Common Stock | 11,900 | 1.31 | 15.6K | 91,444 | D | ↗ |
| 2025-12-12 | Zedelmayer Christine | Officer | S-Sale | D | Common Stock | 23,804 | 1.34 | 31.9K | 103,344 | D | ↗ |
| 2025-11-25 | Zedelmayer Christine | Officer | S-Sale | D | Common Stock | 100 | 0.98 | 98.00 | 135,146 | D | ↗ |
| 2025-08-29 | Zedelmayer Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 725,000 | 1.74 | 1.26M | 725,000 | D | ↗ |
| 2025-08-29 | Tom Penny | Officer | A-Award | A | Employee Stock Option (right to buy) | 525,000 | 1.74 | 913.5K | 525,000 | D | ↗ |
| 2025-08-29 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 1,695,000 | 1.74 | 2.95M | 1,695,000 | D | ↗ |
| 2025-08-29 | Connelly Stephen | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,025,000 | 1.74 | 1.78M | 1,025,000 | D | ↗ |
| 2025-05-21 | Troupin Barbara | Director | A-Award | A | Director Stock Option (right to buy) | 20,000 | 0.39 | 7.8K | 20,000 | D | ↗ |
| 2025-05-21 | Pruzanski Mark | Director | A-Award | A | Director Stock Option (right to buy) | 20,000 | 0.39 | 7.8K | 20,000 | D | ↗ |
| 2025-05-21 | McDermott Charles Douglas | Director | A-Award | A | Director Stock Option (right to buy) | 20,000 | 0.39 | 7.8K | 20,000 | D | ↗ |
| 2025-05-21 | MANIAN BALA S | Director | A-Award | A | Director Stock Option (right to buy) | 20,000 | 0.39 | 7.8K | 20,000 | D | ↗ |
| 2025-05-21 | DEMSKI MARTHA J | Director | A-Award | A | Director Stock Option (right to buy) | 20,000 | 0.39 | 7.8K | 20,000 | D | ↗ |
| 2025-05-21 | Colabuono Peter | Director | A-Award | A | Director Stock Option (right to buy) | 20,000 | 0.39 | 7.8K | 20,000 | D | ↗ |
| 2025-02-14 | Zedelmayer Christine | Officer | D-Return | D | Employee Stock Option (right to buy) | 125,000 | 3.86 | 482.5K | 0 | D | ↗ |
| 2025-02-14 | Troupin Barbara | Director | D-Return | D | Director Stock Option (right to buy) | 40,000 | 3.59 | 143.6K | 0 | D | ↗ |
| 2025-02-14 | Tom Penny | Officer | D-Return | D | Employee Stock Option (right to buy) | 60,000 | 3.86 | 231.6K | 0 | D | ↗ |
| 2025-02-14 | Steel Bruce D. | Director / Officer / 10% Owner | D-Return | D | Employee Stock Option (right to buy) | 100,000 | 4.75 | 475.0K | 0 | D | ↗ |
| 2025-02-14 | Pruzanski Mark | Director | D-Return | D | Director Stock Option (right to buy) | 12,000 | 6.01 | 72.1K | 0 | D | ↗ |
| 2025-02-14 | MANIAN BALA S | Director | A-Award | A | Director Stock Option (right to buy) | 20,634 | 0.79 | 16.2K | 20,634 | D | ↗ |
| 2025-02-14 | Keyes Jason A | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.79 | 137.4K | 175,000 | D | ↗ |
| 2025-02-14 | DEMSKI MARTHA J | Director | D-Return | D | Director Stock Option (right to buy) | 12,000 | 6.01 | 72.1K | 0 | D | ↗ |
| 2025-02-14 | Connelly Stephen | Director / Officer | D-Return | D | Employee Stock Option (right to buy) | 175,000 | 1.06 | 185.5K | 0 | D | ↗ |
| 2025-02-14 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 90,000 | 0.79 | 70.7K | 90,000 | D | ↗ |
| 2025-01-23 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 10,000 | 0.65 | 6.5K | 37,720 | I | ↗ |
| 2025-01-02 | Zedelmayer Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.77 | 134.8K | 175,000 | D | ↗ |
| 2025-01-02 | Tom Penny | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 0.77 | 96.3K | 125,000 | D | ↗ |
| 2025-01-02 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 410,000 | 0.77 | 315.7K | 410,000 | D | ↗ |
| 2025-01-02 | Keyes Jason A | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.77 | 134.8K | 175,000 | D | ↗ |
| 2025-01-02 | Connelly Stephen | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.77 | 134.8K | 175,000 | D | ↗ |
| 2025-01-02 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.77 | 38.5K | 50,000 | D | ↗ |
| 2024-12-11 | Colabuono Peter | Director | A-Award | A | Director Stock Option (right to buy) | 40,000 | 0.70 | 28.0K | 40,000 | D | ↗ |
| 2024-12-10 | Keyes Jason A | Officer | A-Award | A | Common Stock | 15,000 | 0.54 | 8.1K | 88,913 | D | ↗ |
| 2024-11-14 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 10,000 | 0.70 | 7.0K | 47,720 | I | ↗ |
| 2024-10-28 | Zedelmayer Christine | Officer | S-Sale | D | Common Stock | 15,000 | 1.25 | 18.8K | 135,246 | D | ↗ |
| 2024-10-28 | Tom Penny | Officer | S-Sale | D | Common Stock | 2,835 | 1.25 | 3.5K | 6,533 | D | ↗ |
| 2024-10-25 | Tom Penny | Officer | S-Sale | D | Common Stock | 683 | 1.25 | 853.75 | 9,368 | D | ↗ |
| 2024-09-26 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 10,000 | 0.81 | 8.1K | 57,720 | I | ↗ |
| 2024-09-16 | Tom Penny | Officer | S-Sale | D | Common Stock | 38,806 | 0.85 | 33.0K | 10,051 | — | ↗ |
| 2024-07-16 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 10,000 | 0.87 | 8.7K | 67,720 | — | ↗ |
| 2024-05-22 | Xu Yu (Katherine) | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 1.43 | 28.6K | 20,000 | — | ↗ |
| 2024-05-22 | Troupin Barbara | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 1.43 | 28.6K | 20,000 | — | ↗ |
| 2024-05-22 | Pruzanski Mark | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 1.43 | 28.6K | 20,000 | — | ↗ |
| 2024-05-22 | McDermott Charles Douglas | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 1.43 | 28.6K | 20,000 | — | ↗ |
| 2024-05-22 | MANIAN BALA S | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 1.43 | 28.6K | 20,000 | — | ↗ |
| 2024-05-22 | DEMSKI MARTHA J | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 1.43 | 28.6K | 20,000 | — | ↗ |
| 2024-03-06 | Tom Penny | Officer | — | D | Employee Stock Option (right to buy) | 40,000 | 5.03 | 201.2K | 0 | — | ↗ |
| 2024-01-02 | Zedelmayer Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.73 | 127.8K | 175,000 | — | ↗ |
| 2024-01-02 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 410,000 | 0.73 | 299.3K | 410,000 | — | ↗ |
| 2024-01-02 | Rothman Joel | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.73 | 127.8K | 175,000 | — | ↗ |
| 2024-01-02 | Keyes Jason A | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.73 | 127.8K | 175,000 | — | ↗ |
| 2024-01-02 | Connelly Stephen | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.73 | 127.8K | 175,000 | — | ↗ |
| 2024-01-02 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.73 | 36.5K | 50,000 | — | ↗ |
| 2023-12-08 | Zedelmayer Christine | Officer | A-Award | A | Common Stock | 8,804 | 0.58 | 5.1K | 135,246 | — | ↗ |
| 2023-12-08 | Rothman Joel | Officer | A-Award | A | Common Stock | 8,804 | 0.58 | 5.1K | 58,150 | — | ↗ |
| 2023-12-08 | Keyes Jason A | Officer | A-Award | A | Common Stock | 8,805 | 0.58 | 5.1K | 58,913 | — | ↗ |
| 2023-06-09 | Zedelmayer Christine | Officer | A-Award | A | Common Stock | 15,000 | 0.56 | 8.4K | 126,442 | — | ↗ |
| 2023-06-09 | Rothman Joel | Officer | A-Award | A | Common Stock | 15,000 | 0.56 | 8.4K | 49,346 | — | ↗ |
| 2023-06-09 | Keyes Jason A | Officer | A-Award | A | Common Stock | 15,000 | 0.56 | 8.4K | 50,108 | — | ↗ |
| 2023-05-22 | Xu Yu (Katherine) | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2023-05-22 | Troupin Barbara | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2023-05-22 | Pruzanski Mark | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2023-05-22 | McDermott Charles Douglas | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2023-05-22 | MANIAN BALA S | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2023-05-22 | DEMSKI MARTHA J | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.65 | 13.0K | 20,000 | — | ↗ |
| 2023-01-03 | Zedelmayer Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.00 | — | 175,000 | — | ↗ |
| 2023-01-03 | Steel Bruce D. | Officer | A-Award | A | Employee Stock Option (right to buy) | 410,000 | 0.00 | — | 410,000 | — | ↗ |
| 2023-01-03 | Rothman Joel | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.00 | — | 175,000 | — | ↗ |
| 2023-01-03 | Keyes Jason A | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.00 | — | 175,000 | — | ↗ |
| 2023-01-03 | Connelly Stephen | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 0.00 | — | 175,000 | — | ↗ |
| 2023-01-03 | BRADBURY DANIEL | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-12-09 | Rothman Joel | Officer | A-Award | A | Common Stock | 3,821 | 1.19 | 4.5K | 34,346 | — | ↗ |
| 2022-12-09 | Keyes Jason A | Officer | A-Award | A | Common Stock | 4,444 | 1.19 | 5.3K | 35,108 | — | ↗ |
| 2022-08-29 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 7,000 | 2.83 | 19.8K | 77,720 | — | ↗ |
| 2022-06-10 | Zedelmayer Christine | Officer | A-Award | A | Common Stock | 9,033 | 1.85 | 16.7K | 111,442 | — | ↗ |
| 2022-06-10 | Rothman Joel | Officer | A-Award | A | Common Stock | 6,244 | 1.85 | 11.6K | 30,525 | — | ↗ |
| 2022-06-06 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 2.52 | 12.6K | 84,720 | — | ↗ |
| 2022-05-24 | Xu Yu (Katherine) | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-24 | Pruzanski Mark | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-24 | McDermott Charles Douglas | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-24 | MANIAN BALA S | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-24 | DEMSKI MARTHA J | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-04-04 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 8,000 | 3.18 | 25.4K | 89,720 | — | ↗ |
| 2022-03-01 | Troupin Barbara | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-03-01 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 38,000 | 3.59 | 136.4K | 38,000 | — | ↗ |
| 2022-02-24 | Troupin Barbara | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-19 | Zedelmayer Christine | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 3.86 | 482.5K | 125,000 | — | ↗ |
| 2022-01-19 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 325,000 | 3.86 | 1.25M | 325,000 | — | ↗ |
| 2022-01-19 | Rothman Joel | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 3.86 | 482.5K | 125,000 | — | ↗ |
| 2022-01-19 | Keyes Jason A | Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 3.86 | 482.5K | 125,000 | — | ↗ |
| 2022-01-19 | Connelly Stephen | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 125,000 | 3.86 | 482.5K | 125,000 | — | ↗ |
| 2021-12-10 | Rothman Joel | Officer | A-Award | A | Common Stock | 1,290 | 2.35 | 3.0K | 24,281 | — | ↗ |
| 2021-12-10 | Keyes Jason A | Officer | A-Award | A | Common Stock | 5,585 | 2.35 | 13.1K | 23,296 | — | ↗ |
| 2021-12-01 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 5.08 | 25.4K | 97,720 | — | ↗ |
| 2021-11-16 | Zedelmayer Christine | Officer | M-Exempt | A | Common Stock | 15,000 | 2.45 | 36.8K | 109,759 | — | ↗ |
| 2021-10-06 | Connelly Stephen | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 2,467 | 2.80 | 6.9K | 0 | — | ↗ |
| 2021-09-27 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 8,000 | 6.74 | 53.9K | 102,720 | — | ↗ |
| 2021-07-27 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 5.72 | 28.6K | 110,720 | — | ↗ |
| 2021-06-10 | Zedelmayer Christine | Officer | A-Award | A | Common stock, par value $0.0001 per share | 9,032 | 2.35 | 21.2K | 90,509 | — | ↗ |
| 2021-06-10 | Rothman Joel | Officer | A-Award | A | Common stock, par value $0.0001 per share | 7,742 | 2.35 | 18.2K | 22,991 | — | ↗ |
| 2021-06-10 | Keyes Jason A | Officer | A-Award | A | Common stock, par value $0.0001 per share | 5,535 | 2.35 | 13.0K | 17,711 | — | ↗ |
| 2021-06-08 | Connelly Stephen | Director / Officer | M-Exempt | A | Common Stock | 10,495 | 4.75 | 49.9K | 1,003,495 | — | ↗ |
| 2021-06-07 | Connelly Stephen | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 8,490 | 2.80 | 23.8K | 0 | — | ↗ |
| 2021-06-04 | Connelly Stephen | Director / Officer | S-Sale | D | Common Stock | 6,509 | 7.01 | 45.6K | 993,000 | — | ↗ |
| 2021-05-26 | Pruzanski Mark | Director | A-Award | A | Stock Option (right to buy) | 20,770 | 6.55 | 136.0K | 20,770 | — | ↗ |
| 2021-05-26 | McDermott Charles Douglas | Director | A-Award | A | Stock Option (right to buy) | 20,770 | 6.55 | 136.0K | 20,770 | — | ↗ |
| 2021-05-26 | MANIAN BALA S | Director | A-Award | A | Stock Option (right to buy) | 20,770 | 6.55 | 136.0K | 20,770 | — | ↗ |
| 2021-05-26 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 6.50 | 32.5K | 115,720 | — | ↗ |
| 2021-05-26 | DEMSKI MARTHA J | Director | A-Award | A | Stock Option (right to buy) | 20,770 | 6.55 | 136.0K | 20,770 | — | ↗ |
| 2021-03-04 | Xu Yu (Katherine) | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 6.69 | 200.7K | 30,000 | — | ↗ |
| 2021-02-05 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | — | I | Warrant (right to buy) | 985,713 | 14.00 | 13.80M | 0 | — | ↗ |
| 2021-02-04 | Xu Yu (Katherine) | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-26 | Rothman Joel | Officer | — | D | Common Stock | 0 | 0.00 | — | 15,249 | — | ↗ |
| 2021-01-11 | Thomas Dolca | Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 5.20 | 2.34M | 450,000 | — | ↗ |
| 2021-01-04 | Zedelmayer Christine | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 5.03 | 503.0K | 100,000 | — | ↗ |
| 2021-01-04 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 245,000 | 5.03 | 1.23M | 245,000 | — | ↗ |
| 2021-01-04 | Keyes Jason A | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 5.03 | 503.0K | 100,000 | — | ↗ |
| 2021-01-04 | Connelly Stephen | Director / Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 5.03 | 503.0K | 100,000 | — | ↗ |
| 2021-01-04 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 36,000 | 5.03 | 181.1K | 36,000 | — | ↗ |
| 2020-12-28 | Connelly Stephen | Director / Officer | S-Sale | D | Common Stock | 25,000 | 4.52 | 113.0K | 993,000 | — | ↗ |
| 2020-12-23 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 8,000 | 4.74 | 37.9K | 120,720 | — | ↗ |
| 2020-12-10 | Zedelmayer Christine | Officer | J-Other | A | Common Stock | 1,097 | 2.35 | 2.6K | 81,477 | — | ↗ |
| 2020-12-10 | Keyes Jason A | Officer | J-Other | A | Common Stock | 5,362 | 2.35 | 12.6K | 12,176 | — | ↗ |
| 2020-09-28 | Connelly Stephen | Director / Officer | S-Sale | D | Common Stock | 25,000 | 5.62 | 140.4K | 1,018,000 | — | ↗ |
| 2020-07-13 | Connelly Stephen | Director / Officer | S-Sale | D | Common Stock | 250,000 | 8.13 | 2.03M | 1,043,000 | — | ↗ |
| 2020-06-10 | Zedelmayer Christine | Officer | J-Other | A | Common Stock | 9,570 | 2.41 | 23.1K | 80,380 | — | ↗ |
| 2020-06-10 | Keyes Jason A | Officer | J-Other | A | Common Stock | 5,014 | 2.41 | 12.1K | 6,814 | — | ↗ |
| 2020-05-28 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 100,110 | 3.53 | 353.4K | 100,110 | — | ↗ |
| 2020-05-28 | McDermott Charles Douglas | Director | A-Award | A | Stock Option (right to buy) | 19,916 | 3.53 | 70.3K | 19,916 | — | ↗ |
| 2020-05-28 | MANIAN BALA S | Director | A-Award | A | Stock Option (right to buy) | 20,634 | 3.53 | 72.8K | 20,634 | — | ↗ |
| 2020-05-28 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 28,708 | 3.53 | 101.3K | 28,708 | — | ↗ |
| 2020-05-19 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 60,000 | 2.80 | 168.0K | 60,000 | — | ↗ |
| 2020-05-19 | Pruzanski Mark | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 2.80 | 67.2K | 24,000 | — | ↗ |
| 2020-05-19 | McDermott Charles Douglas | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 2.80 | 67.2K | 24,000 | — | ↗ |
| 2020-05-19 | MANIAN BALA S | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 2.80 | 67.2K | 24,000 | — | ↗ |
| 2020-05-19 | DEMSKI MARTHA J | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 2.80 | 67.2K | 24,000 | — | ↗ |
| 2020-05-19 | Connelly Stephen | Director / Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 2.80 | 168.0K | 60,000 | — | ↗ |
| 2020-04-22 | Zedelmayer Christine | Officer | D-Return | D | Stock Option (right to buy) | 90,000 | 4.75 | 427.5K | 0 | — | ↗ |
| 2020-04-22 | Polu Krishna R | Officer | D-Return | D | Stock Option (right to buy) | 90,000 | 7.16 | 644.4K | 0 | — | ↗ |
| 2020-04-22 | Keyes Jason A | Officer | D-Return | D | Stock Option (right to buy) | 70,000 | 7.16 | 501.2K | 0 | — | ↗ |
| 2020-02-18 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 5.03 | 25.1K | 130,520 | — | ↗ |
| 2020-01-21 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 4.41 | 22.0K | 135,520 | — | ↗ |
| 2020-01-01 | Zedelmayer Christine | Officer | — | D | Common Stock | 0 | 0.00 | — | 70,810 | — | ↗ |
| 2019-12-10 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 100,000 | 4.75 | 475.0K | 100,000 | — | ↗ |
| 2019-12-10 | Polu Krishna R | Officer | A-Award | A | Stock Option (right to buy) | 125,000 | 4.75 | 593.8K | 125,000 | — | ↗ |
| 2019-12-10 | Keyes Jason A | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 4.75 | 427.5K | 90,000 | — | ↗ |
| 2019-12-10 | Connelly Stephen | Director / Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 4.75 | 427.5K | 90,000 | — | ↗ |
| 2019-12-10 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 36,000 | 4.75 | 171.0K | 36,000 | — | ↗ |
| 2019-09-03 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 3.60 | 18.0K | 138,720 | — | ↗ |
| 2019-08-01 | Keyes Jason A | Officer | S-Sale | D | Common Stock | 5,000 | 3.99 | 19.9K | 143,720 | — | ↗ |
| 2019-06-11 | Pruzanski Mark | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.01 | 72.1K | 12,000 | — | ↗ |
| 2019-06-11 | McDermott Charles Douglas | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.01 | 72.1K | 12,000 | — | ↗ |
| 2019-06-11 | MANIAN BALA S | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.01 | 72.1K | 12,000 | — | ↗ |
| 2019-06-11 | DEMSKI MARTHA J | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.01 | 72.1K | 12,000 | — | ↗ |
| 2019-02-13 | Steel Bruce D. | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 45,648 | 7.88 | 359.7K | 45,648 | — | ↗ |
| 2019-02-13 | Polu Krishna R | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 7.16 | 644.4K | 90,000 | — | ↗ |
| 2019-02-13 | Keyes Jason A | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 7.16 | 501.2K | 70,000 | — | ↗ |
| 2019-02-13 | Connelly Stephen | Director / Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 7.16 | 644.4K | 90,000 | — | ↗ |
| 2019-02-13 | BRADBURY DANIEL | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 90,000 | 7.16 | 644.4K | 90,000 | — | ↗ |
| 2018-10-16 | Steel Bruce D. | Director / Officer | J-Other | A | Common Stock | 48,495 | 11.20 | 543.1K | 48,495 | — | ↗ |
| 2018-10-16 | Biocon SA | 10% Owner | A-Award | A | Common Stock | 228,060 | 0.00 | — | 2,316,134 | — | ↗ |
| 2018-10-16 | BRADBURY DANIEL | Director / Officer | J-Other | A | Common Stock | 38,796 | 11.20 | 434.5K | 2,969,596 | — | ↗ |
| 2018-10-11 | Steel Bruce D. | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 431,000 | — | ↗ |
| 2018-10-11 | Pruzanski Mark | Director | — | D | Common Stock | 0 | 0.00 | — | 23,799 | — | ↗ |
| 2018-10-11 | Polu Krishna R | Officer | — | D | Stock Option (right to buy) | 208,216 | 3.30 | 687.1K | 0 | — | ↗ |
| 2018-10-11 | McDermott Charles Douglas | Director | — | I | Common Stock | 0 | 0.00 | — | 23,799 | — | ↗ |
| 2018-10-11 | MANIAN BALA S | Director | — | D | Common Stock | 0 | 0.00 | — | 23,799 | — | ↗ |
| 2018-10-11 | Keyes Jason A | Officer | — | I | Common Stock | 0 | 0.00 | — | 148,720 | — | ↗ |
| 2018-10-11 | DEMSKI MARTHA J | Director | — | I | Common Stock | 0 | 0.00 | — | 23,799 | — | ↗ |
| 2018-10-11 | Connelly Stephen | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 1,293,000 | — | ↗ |
| 2018-10-11 | Biocon SA | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,088,074 | — | ↗ |
| 2018-10-11 | BRADBURY DANIEL | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 2,930,800 | — | ↗ |
| 2009-07-01 | Toussaint Claudia S | Officer | D-Return | D | NQ Stock Option | 3,886 | 45.19 | 175.6K | 0 | — | ↗ |
| 2009-07-01 | SHERN STEPHANIE M | Director | D-Return | D | Common Stock | 7,842 | 0.00 | — | 0 | — | ↗ |
| 2009-07-01 | Paliwal Dinesh C | Director | D-Return | D | Common Stock | 6,981 | 0.00 | — | 0 | — | ↗ |
| 2009-07-01 | OWENS WILLIAM ARTHUR | Director | D-Return | D | Common Stock | 11,993 | 0.00 | — | 0 | — | ↗ |
| 2009-07-01 | Huber Dennis G | Officer | D-Return | D | NQ Stock Option | 23,728 | 41.94 | 995.2K | 0 | — | ↗ |
| 2009-07-01 | GERKE THOMAS A | Director / Officer | D-Return | D | NQ Stock Option | 9,495 | 48.10 | 456.7K | 0 | — | ↗ |
| 2009-07-01 | GEPHARDT Richard A | Director | D-Return | D | Common Stock | 1,879 | 0.00 | — | 0 | — | ↗ |
| 2009-07-01 | Davis Steven A | Director | D-Return | D | Common Stock | 6,981 | 0.00 | — | 0 | — | ↗ |
| 2009-07-01 | BETTS GENE M | Officer | D-Return | D | NQ Stock Option | 6,385 | 43.06 | 274.9K | 0 | — | ↗ |
| 2009-05-21 | Toussaint Claudia S | Officer | M-Exempt | A | Common Stock | 1,316 | 0.00 | — | 13,384 | — | ↗ |
| 2009-05-21 | Huber Dennis G | Officer | F-InKind | D | Common Stock | 1,269 | 40.24 | 51.1K | 23,999 | — | ↗ |
| 2009-05-21 | GERKE THOMAS A | Officer | F-InKind | D | Common Stock | 4,556 | 40.24 | 183.3K | 64,039 | — | ↗ |
| 2009-05-21 | BETTS GENE M | Officer | F-InKind | D | Common Stock | 3,040 | 40.24 | 122.3K | 37,920 | — | ↗ |
| 2009-05-01 | SHERN STEPHANIE M | Director | M-Exempt | A | Common Stock | 1,879 | 0.00 | — | 7,842 | — | ↗ |
| 2009-05-01 | Paliwal Dinesh C | Director | M-Exempt | D | Restricted Stock Units | 1,879 | 0.00 | — | 0 | — | ↗ |
| 2009-05-01 | OWENS WILLIAM ARTHUR | Director | M-Exempt | D | Restricted Stock Units | 1,879 | 0.00 | — | 5,012 | — | ↗ |
| 2009-05-01 | GEPHARDT Richard A | Director | M-Exempt | A | Common Stock | 1,879 | 0.00 | — | 1,879 | — | ↗ |
| 2009-05-01 | Davis Steven A | Director | M-Exempt | D | Restricted Stock Units | 1,879 | 0.00 | — | 0 | — | ↗ |
| 2009-04-30 | SHERN STEPHANIE M | Director | M-Exempt | D | Restricted Stock Units | 3,720 | 0.00 | — | 1,879 | — | ↗ |
| 2009-04-30 | Paliwal Dinesh C | Director | M-Exempt | D | Restricted Stock Units | 3,720 | 0.00 | — | 1,879 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-16.9K
Shares Outstanding
35.52M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Bruce D. Steel Chief Executive Officer | 519.2K | 353.5K | — | 3.02M | 361.8K | — | 4.26M | 70.99% | ↗ |
| 2 | 2025 | Stephen Connelly, Ph.D. President and Chief Scientific Officer | 455.2K | 271.4K | — | 1.78M | 200.0K | — | 2.70M | 65.71% | ↗ |
| 3 | 2025 | Christine Zedelmayer Chief Operating Officer | 441.3K | 175.0K | — | 1.29M | 194.0K | — | 2.10M | 61.45% | ↗ |
| 4 | 2024 | Bruce D. Steel Chief Executive Officer | 471.3K | — | — | 213.1K | — | — | 684.4K | 31.13% | ↗ |
| 5 | 2024 | Bruce D. Steel President and Chief Executive Officer | 471.3K | — | — | 213.1K | — | — | 648.4K | 32.86% | ↗ |
| 6 | 2024 | Stephen Connelly, Ph.D. Chief Scientific Officer | 428.5K | — | — | 90.9K | — | — | 519.4K | 17.51% | ↗ |
| 7 | 2024 | Stephen Connelly, Ph.D. President and Chief Scientific Officer | 428.5K | — | — | 90.9K | — | — | 519.4K | 17.51% | ↗ |
| 8 | 2024 | Christine Zedelmayer Chief Operating Officer | 415.3K | — | — | 90.9K | — | — | 506.2K | 17.96% | ↗ |
| 9 | 2023 | Bruce D. Steel President and Chief Executive Officer | 455.4K | — | — | 568.3K | 324.5K | — | 1.35M | 42.16% | ↗ |
| 10 | 2023 | Stephen Connelly, Ph.D. Chief Scientific Officer | 414.0K | — | — | 255.9K | 157.3K | — | 827.3K | 30.94% | ↗ |
| 11 | 2023 | Christine Zedelmayer Senior Vice President, Chief Operating Officer | 401.3K | — | — | 231.8K | 152.5K | — | 785.5K | 29.51% | ↗ |
| 12 | 2023 | Christine Zedelmayer Chief Operating Officer | 401.3K | — | — | 231.8K | 152.5K | — | 785.5K | 29.51% | ↗ |
| 13 | 2022 | Bruce D. Steel President and Chief Executive Officer | 455.4K | — | — | 881.9K | 341.6K | — | 1.68M | 52.53% | ↗ |
| 14 | 2022 | Stephen Connelly, Ph.D. Chief Scientific Officer | 414.0K | — | — | 339.2K | 165.6K | — | 918.8K | 36.92% | ↗ |
| 15 | 2022 | Christine Zedelmayer Senior Vice President, Chief Operating Officer | 401.3K | — | — | 339.2K | 160.5K | — | 900.9K | 37.65% | ↗ |
| 16 | 2021 | Dolca Thomas, M.D. Former Executive Vice President, Research and Development and Chief Medical Officer | 470.4K | — | — | 1.72M | 146.3K | — | 2.34M | 73.61% | ↗ |
| 17 | 2021 | Bruce D. Steel President and Chief Executive Officer | 440.0K | — | — | 903.7K | 208.6K | — | 1.55M | 58.22% | ↗ |
| 18 | 2021 | Stephen Connelly, Ph.D. Chief Scientific Officer | 400.0K | — | — | 368.8K | 126.4K | — | 895.2K | 41.20% | ↗ |
| 19 | 2020 | Bruce D. Steel President and Chief Executive Officer | 198.4K | — | — | 367.9K | 216.0K | — | 782.3K | 47.03% | ↗ |
| 20 | 2020 | Stephen Connelly, Ph.D. Chief Scientific Officer | 386.3K | — | — | 123.2K | 130.4K | — | 639.8K | 19.26% | ↗ |
| 21 | 2020 | Krishna R. Polu, M.D. Former Executive Vice President, Research and Development and Chief Medical Officer | 450.0K | — | — | — | 162.0K | — | 612.0K | 0.00% | ↗ |
| 22 | 2019 | Krishna R. Polu, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 409.4K | — | — | 951.4K | 147.4K | — | 1.51M | 63.08% | ↗ |
| 23 | 2019 | Krishna R. Polu, M.D. Former Executive Vice President, Research and Development and Chief Medical Officer | 409.4K | — | — | 951.4K | 147.4K | — | 1.51M | 63.08% | ↗ |
| 24 | 2019 | Bruce D. Steel President and Chief Executive Officer; former Chief Business Offer | 395.8K | — | — | 820.5K | 142.5K | — | 1.36M | 60.38% | ↗ |
| 25 | 2019 | Bruce D. Steel President and Chief Executive Officer | 395.8K | — | — | 820.5K | 142.5K | — | 1.36M | 60.38% | ↗ |
| 26 | 2019 | Daniel M. Bradbury Executive Chairman of the Board of Directors; former Chief Executive Officer | 425.0K | — | — | 625.4K | 153.0K | — | 1.20M | 51.97% | ↗ |
| 27 | 2019 | Stephen Connelly, Ph.D. Chief Scientific Officer | 362.5K | — | — | — | 122.3K | — | 484.8K | 0.00% | ↗ |
| 28 | 2018 | Krishna R. Polu, M.D. Chief Medical Officer | 143.8K | — | — | 2.15M | 43.1K | — | 2.34M | 92.00% | ↗ |
| 29 | 2018 | Krishna R. Polu, M.D. Executive Vice President, Research and Development and Chief Medical Officer | 143.8K | — | — | 2.15M | 43.1K | — | 2.34M | 92.00% | ↗ |
| 30 | 2018 | Stephen Connelly, Ph.D. Chief Scientific Officer | 268.8K | — | — | — | 105.0K | — | 373.8K | 0.00% | ↗ |
| 31 | 2018 | Daniel M. Bradbury Executive Chairman of the Board of Directors; former Chief Executive Officer | 233.3K | — | — | — | 81.7K | — | 315.0K | 0.00% | ↗ |
| 32 | 2018 | Daniel M. Bradbury Chief Executive Officer | 233.3K | — | — | — | 81.7K | — | 315.0K | 0.00% | ↗ |
| 33 | 2018 | Bruce D. Steel President and Chief Executive Officer; former Chief Business Offer | 218.8K | — | — | — | 76.6K | — | 295.3K | 0.00% | ↗ |
| 34 | 2017 | Stephen Connelly, Ph.D. Chief Scientific Officer | 30.0K | — | — | — | — | — | 30.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bruce D. Steel | Co-Founder, Chief Executive Officer & Director | 1M | male |
| Stephen Connelly | Chief Scientific Officer & President | 926.6K | — |
| Christine Zedelmayer | Senior Vice President & Chief Operating Officer | 810.3K | female |
| Lisette Acevedo | Vice President of Clinical Development | — | — |
| Michael Moore | Vice President of Investor Relations & Corporate Communications | — | male |
| Penny Tom | Senior Vice President of Finance & Principal Accounting Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
